Welcome to our dedicated page for MedWellAI news (Ticker: MWAI), a resource for investors and traders seeking the latest updates and insights on MedWellAI stock.
MedWellAi, Inc. (MWAI) is an AI-driven healthcare and wellness company that has publicly detailed a transformation into an integrated ecosystem spanning B2B pharmaceutical distribution, telemedicine platforms, and health-focused real estate and software. Its news flow centers on developments within this ecosystem, including new platform launches, technology partnerships, and corporate branding changes.
Recent company announcements describe MedWellAi’s rebranding from Integrated Ventures, Inc. to MedWellAi, Inc., along with the adoption of the MWAI trading symbol on the OTCQB market. News releases also outline the launch and evolution of MedWell USA, LLC, a B2B e-commerce ordering portal and distribution channel for pharma products aimed at medical offices, wellness clinics, gyms, and online telemedicine companies, supported by agreements with a licensed pharmaceutical supplier and an AI software partner.
Another key theme in MedWellAi’s news is the development of TeleMD.Ai, a B2B/B2C telemedicine platform operated by MedWell Direct, LLC. Company news describes a software development agreement with BrighterMD (Doctegrity) to build TeleMD.Ai as a nationwide telehealth and wellness platform focused on corporate healthcare benefits. Releases detail planned features such as subscription-based primary care telemedicine, telehealth therapy consultations, behavioral and mental health benefits, lifestyle and wellness programs, pharmacy discount benefits, and AI agents for personalized healthcare assessments.
News items also highlight MedWell Facilities, LLC, which focuses on health and wellness real estate and AI-driven clinic optimization software, including the launch of a managed location in partnership with a fitness club and a wellness tenant. Investors and observers following MWAI news can expect updates on telemedicine platform progress, new partnerships, product and service expansions within the wellness and pharmacy benefits space, and further developments in its AI-enabled healthcare infrastructure.
MedWell Ai (OTCQB:MWAI) reported Q2 FY2025 revenue of $548,315 and provided full‑year 2025 guidance exceeding $2,200,000. Revenues rose ~280% YoY for the quarter and ~700% for six months. Net loss, operating expenses and liabilities were materially reduced versus prior periods.
Key metrics: Q2 revenue $548,315; six‑month revenue $1,075,806; Q2 net loss $266,221; total liabilities/deficit $468,655.
MedWell Ai (OTCQB: MWAI) signed a Letter of Intent to form a vertically integrated regenerative wellness platform organized into three divisions: national pharma distribution and telemed, surgical and cosmetic centers with a men's franchise, and advanced biologics/product innovation.
The consolidation targets Ageless Cosmetic Surgery Centers, Apollo BioWellness (OTC: KOAN) and Evolutionary Biologics, plus MedWell USA. Trailing 2025 revenues totaled $14 million; the consolidated company is projected to exceed $25 million in 2026 with conservative EBITDA margins ≥20%, subject to funding and successful closings within a targeted 60 days.
Market context cites a USD 35.5B regenerative medicine market in 2024, expanding toward USD 169B by 2034 and a USD 6.3T global wellness economy in 2023.
MedWell Ai (OTCQB: MWAI) has partnered with BrighterMD to develop TeleMD.Ai, a comprehensive B2B and B2C healthcare telemedicine platform targeting the $24.46 billion corporate wellness market. Set to launch in October 2025, the platform will offer unlimited access to healthcare providers and certified telehealth therapists through subscription-based plans.
TeleMD.Ai's key features include 24/7 nationwide access, primary care telemedicine, mental health services, AI-enhanced personalized healthcare assessments, bilingual services, and a FREE LifeVitals app for biometric monitoring. The platform will integrate with 70,000+ pharmacies offering prescription benefits with up to 80% savings and no-cost access to 125 commonly prescribed medications.
MedWell Ai (OTCQB: MWAI), formerly Integrated Ventures, has completed its corporate rebranding and transformation into an AI-driven healthcare ecosystem. The company announced several key developments including a new trading symbol, corporate website, and the launch of multiple business operations.
The company's operations now comprise three main subsidiaries: MedWell USA, LLC (B2B e-commerce portal for pharma products), TeleMD.Ai (telemedicine platform under development), and MedWell Facilities, LLC (real estate and AI software platform for wellness clinics). MedWell USA has secured revenue share distribution and master licensing agreements for its e-commerce platform, which features over 80 products.